Now that the first study sites have been initiated, we can start collecting clinical data. Data on the use of cangrelor in high-risk patients with acute myocardial infarction and PCI who have experienced CPR, cardiogenic shock or received mechanical or non-invasive ventilation will be collected from pre-existing clinical documentation and systematically analyzed. The register trial has also been extended to include clinical trial sites in Austria in order to be able to generate a significant number of patient outcomes. The goal is to generate clinical data from approximately 450 consecutive patients within the next six months.
Another important milestone has been achieved, allowing the Institute for Myocardial Infarction Research to generate new data to understand the efficacy and safety of cangrelor in high-risk patients.Read more
Day-to-day research results on the COVID-19 situation in hospitals, based on our own COVID-19 registry.Read more
Presentation of the second evaluation of the COVID-19 registry for Rhineland-Palatinate by Dr. Anselm K. Gitt, board of directors of Foundation Institute for Myocardial Infarction Research in and study director of the COVID-19 registry...Read more